GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Prestige Consumer Healthcare Inc (NYSE:PBH) » Definitions » Financial Strength

Prestige Consumer Healthcare (Prestige Consumer Healthcare) Financial Strength : 5 (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Prestige Consumer Healthcare Financial Strength?

Prestige Consumer Healthcare has the Financial Strength Rank of 5.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Prestige Consumer Healthcare's Interest Coverage for the quarter that ended in Dec. 2023 was 5.24. Prestige Consumer Healthcare's debt to revenue ratio for the quarter that ended in Dec. 2023 was 1.07. As of today, Prestige Consumer Healthcare's Altman Z-Score is 2.16.


Competitive Comparison of Prestige Consumer Healthcare's Financial Strength

For the Drug Manufacturers - Specialty & Generic subindustry, Prestige Consumer Healthcare's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prestige Consumer Healthcare's Financial Strength Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Prestige Consumer Healthcare's Financial Strength distribution charts can be found below:

* The bar in red indicates where Prestige Consumer Healthcare's Financial Strength falls into.



Prestige Consumer Healthcare Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Prestige Consumer Healthcare's Interest Expense for the months ended in Dec. 2023 was $-17 Mil. Its Operating Income for the months ended in Dec. 2023 was $87 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,206 Mil.

Prestige Consumer Healthcare's Interest Coverage for the quarter that ended in Dec. 2023 is

Interest Coverage=-1*Operating Income (Q: Dec. 2023 )/Interest Expense (Q: Dec. 2023 )
=-1*86.832/-16.575
=5.24

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Prestige Consumer Healthcare's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(7.838 + 1205.673) / 1130.964
=1.07

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Prestige Consumer Healthcare has a Z-score of 2.16, indicating it is in Grey Zones. This implies that Prestige Consumer Healthcare is in some kind of financial stress. If it is below 1.81, the company may faces bankrupcy risk.

Warning Sign:

Altman Z-score of 2.16 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prestige Consumer Healthcare  (NYSE:PBH) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Prestige Consumer Healthcare has the Financial Strength Rank of 5.


Prestige Consumer Healthcare Financial Strength Related Terms

Thank you for viewing the detailed overview of Prestige Consumer Healthcare's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Prestige Consumer Healthcare (Prestige Consumer Healthcare) Business Description

Traded in Other Exchanges
Address
660 White Plains Road, Tarrytown, NY, USA, 10591
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Executives
Mary Beth Fritz officer: Senior VP Quality & Regulatory 660 WHITE PLAINS RD, 2ND FL, TARRYTOWN NY 10591
Ronald M. Lombardi officer: Chief Executive Officer 660 WHITE PLAINS RD., TARRYTOWN NY 10591
James Darecca director C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Christine Sacco officer: Chief Financial Officer C/O SMART BALANCE, INC., 115 WEST CENTURY ROAD, SUITE 260, PARAMUS NJ 07652
Adel Mekhail other: EVP, Marketing & Sales 660 WHITE PLAINS RD., 2ND FL, TARRYTOWN NY 10591
William P'pool officer: See Remarks 2400 WEST LLOYD EXPRESSWAY, EVANSVILLE IL 47721
Celeste A. Clark director C/O ADVANCEPIERRE FOODS HOLDINGS, INC., 9987 CARVER ROAD, BLUE ASH OH 45242
Christopher J Coughlin director
Natale S Ricciardi director C/O MORRIS COMMUNICATIONS CORP, 725 BROAD ST., AUGUSTA GA 30903
James M Jenness director PO BOX 3599, BATTLECREEK MI 49016-3599
John E Byom director 660 WHITE PLAINS RD., TARRYTOWN NY 10591
Sheila Hopkins director C/O WARNACO INC, 90 PARK AVENUE, NEW YORK NY 10016
Dawn M. Zier director 600 OFFICE CENTER DRIVE, FORT WASHINGTON PA 19034
Jeffrey Zerillo officer: Senior VP Operations 660 WHITE PLAINS RD, 2ND FL, TARRYTOWN NY 10591
Timothy Connors officer: Chief Marketing Officer 660 WHITE PLAINS RD., SUITE 205, TARRYTOWN NY 10591